Abstract

In myotonic dystrophy type 1 (DM1), the association between mutation size (CTG expansion) and the severity of cardiac involvement is controversial. We selected 855 patients with DM1 (women, 51%; median age, 37 years) with genetic testing performed at the moment of their initial cardiac evaluation, out of 1014 patients included in the DM1-Heart Registry between January 2000 and December 2015. We studied the association between CTG expansion size and other baseline characteristics and (i) cardiac involvement at baseline and (ii) the incidence of death, sudden death, and other cardiac adverse events. At initial presentation, the median CTG expansion size was 530 (interquartile range, 300–830). In multivariate analysis, larger expansions were associated with the presence at baseline of conduction defects on the electrocardiogram and left ventricular systolic dysfunction. In a median 11.5 years follow-up period, 210 patients died (25%), including 32 suddenly (4%). Supraventricular arrhythmias developed over lifetime in 166 patients (19%), sustained ventricular tachyarrhythmias in 17 (2%) and permanent pacemakers were implanted in 181 (21%). In Cox-regression analyses, larger CTG expansions were significantly associated with (i) total death, sudden death, and pacemaker implantation in a model including CTG expansion size, age, gender, diabetes and (ii) all endpoints except sudden death in a model including all baseline characteristics. The size of the CTG expansion in the blood of DM1 patients is associated with total and sudden deaths, conduction defects, left ventricular dysfunction and supraventricular arrhythmias.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call